Palisade Bio initiated with an Outperform at Wolfe Research

Wolfe Research analyst Andy Chen initiated coverage of Palisade Bio (PALI) with an Outperform rating and $7 price target The firm sees a “quiet 2026,” but is bullish into ulcerative colitis data due in the second half of 2027 with the mechanism and the firm’s analyses supporting a favorable outcome despite mixed drug class data in the same indication, the analyst tells investors.